Counterfeit weight-loss drugs and ingredients pose a serious threat to Coloradans' health and well-being. The emergence of a gray market for GLP-1 medications demands urgent action from state leaders to protect residents.
As a physician assistant, I've dedicated my career to patient care, advocating for safe and effective treatments. Yet, the proliferation of counterfeit and illegally compounded GLP-1 medications and active pharmaceutical ingredients (APIs) is deeply concerning. Colorado families deserve better, and it's imperative that we address this issue head-on.
GLP-1 therapies have revolutionized obesity management, improving heart health, metabolic risk, and overall well-being. Governor Jared Polis's recent legislation (https://leg.colorado.gov/bills/sb25-048) to expand access to weight loss treatments, including employer coverage options, is a positive step. When used under medical supervision, these drugs can help patients manage their weight with dignity and support. With obesity affecting over 24% of adults in Colorado, ensuring access to FDA-approved weight loss drugs is crucial for public health.
However, the growing demand has led to a dark side. Unscrupulous actors are exploiting patients' needs by selling unapproved, clandestine, and potentially unsafe alternatives, bypassing regulated care. This crisis began with legitimate GLP-1 shortages, prompting compounding pharmacies to step in as a temporary solution. But these efforts should have been short-term, carefully regulated measures.
Regrettably, some med-spas, telehealth companies, and compounding entities have continued to compound or supply GLP-1s, often sourcing APIs from abroad through unregulated importers. These compounds lack FDA approval, resulting in manufacturing processes devoid of the rigorous safety, labeling, and oversight that patients deserve. Even more alarming, some companies are selling raw APIs directly to consumers for home reconstitution, turning a medication requiring medical supervision into a DIY experiment.
The consequences are dire. As of July 2025, federal data reveal hundreds of adverse events linked to compounded or illicit GLP-1s, including hospitalizations, overdoses, and even deaths. These are not mere statistics; they represent real people whose lives and trust in the healthcare system have been affected.
We cannot ignore this crisis. The federal government should strengthen enforcement to prevent illicit APIs from entering U.S. supply chains, as Attorney General Phil Weiser and Colorado congressional members have advocated. Simultaneously, Colorado's regulators, licensing boards, and legislators must take decisive action to shut down illegal compounders, hold accountable those misleading patients, and ensure access to safe, FDA-regulated medications.
My commitment to becoming a PA stems from a belief in equitable, safe, and compassionate healthcare. As a clinician, I've supported patients in making difficult health decisions. As a Coloradan, I advocate for transparency, dignity, and protection, especially in healthcare. By heeding this call, our leaders can safeguard obesity treatments as tools of healing, not shortcuts to danger.
Your support is vital to our mission. (https://coloradonewsline.com/donate/?oa_referrer=midstorybox)
